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Abstract 
Lidocaine is a commonly used local anaesthetic that, besides blocking 
voltage-dependent Na+ channels, has multiple inhibitory effects on muscle-type 
nicotinic acetylcholine (ACh) receptors (nAChRs). In the present study, we have 
investigated the effects of lidocaine on ACh-elicited currents (IAChs) from 
cultured mouse superior cervical ganglion (SCG) neurons, which mainly 
express heteromeric α3β4 nAChRs. Neurons were voltage-clamped by using 
the perforated-patch method and IAChs were elicited by fast application of ACh 
(100-300 µM), either alone or in presence of lidocaine at different 
concentrations. 
IAChs were reversibly blocked by lidocaine in a concentration-dependent 
way (IC50 = 41 µM; nH close to 1) and the inhibition was, at least partially, 
voltage-dependent, indicating an open-channel blockade. Besides, lidocaine 
blocked resting (closed) nAChRs, as evidenced by the increased inhibition 
caused by a 12 s lidocaine application just before its co-application with the 
agonist, and also enhanced IAChs desensitisation, at concentrations close to the 
IC50. 
These results indicate that lidocaine has diverse inhibitory actions on 
neuronal heteromeric nAChRs resembling those previously reported for 
Torpedo (muscle-type) nAChRs (Alberola-Die et al., 2011). The similarity of 
lidocaine actions on different subtypes of heteromeric nAChRs differs with the 
specific effects of other compounds, restricted to particular subtypes of 
nAChRs. 
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1. Introduction 
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated 
ion channels (LGICs) that mediate fast synaptic transmission in peripheral and 
central nervous system. An outstanding characteristic of nAChRs is their wide 
structural heterogeneity, based in both diverse subunit composition and 
stoichiometry, which associates to subtype-specific functional and 
pharmacological properties (Gotti and Clementi, 2004; Dani and Bertrand, 
2007). So far, the most studied, and yet the prototypic model for these 
receptors, is the muscle-type nAChR, localised at the neuromuscular junction of 
vertebrates and at the electrocytes of some electric fishes, and composed of 
two α1 subunits and one β1, γ and δ or ε subunits. In the peripheral and central 
nervous system there are different subtypes of nAChRs, generically called 
neuronal nAChRs. In mammalian autonomic ganglia neurons, including the 
superior cervical ganglion (SCG), the predominant nAChR is the heteromeric 
α3β4 subtype, though there are a significant percentage of combinations with 
α5 and/or β2 subunits (Gotti et al., 2009; David et al., 2010). Moreover, 
homomeric α7 receptors are also present, but their currents are only evoked in 
the presence of PNU 120569 (David et al., 2010). Finally, the two main nAChRs 
subtypes in the mammalian central nervous system are α4β2 and α7 (Flores et 
al., 1992; Barrera and Edwardson, 2008) though combinations of α (2-5) with β 
(2-4) subunits and receptors formed by α9 and/or α10 are also present (Dani 
and Bertrand, 2007). 
Though lidocaine is one of the local anaesthetics (LAs) more commonly 
used in clinical practice, its detailed mechanisms of action on muscle-type 
nAChRs have been only recently studied (Alberola-Die et al., 2011); in fact most 
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studies used permanent-charged lidocaine-analogues such as QX-314 or QX-
222 (Neher and Steinbach, 1978; Pascual and Karlin, 1998; Papke et al., 2001). 
In contrast to QX-314 or QX-222, the molecule of lidocaine has a tertiary amine 
group, so that, at physiological pH, a fraction of the lidocaine molecules remains 
uncharged. The simultaneous presence of both forms of lidocaine, charged and 
neutral, seems to be responsible for the multiple inhibitory actions of lidocaine 
on muscle-type nAChRs from Torpedo marmorata microtransplanted to 
Xenopus oocytes, which include open-channel blockade, enhancement of 
desensitisation, and blockade of closed-state (resting) receptors (Alberola-Die 
et al., 2011). The aim of the present study was to characterize in mouse SCG 
neurons the effects of lidocaine on acetylcholine-elicited currents (IACh), which 
are mainly mediated by heteromeric α3β4 nAChRs. 
2. Materials and methods 
2.1. Animals 
Animal handling and experimental procedures were approved by the 
Spanish Higher Research Council and the University of Vigo Scientific 
Committee and they conformed to Spanish and European guidelines for the 
protection of experimental animals (RD1201/2005; 2010/63/UE). 
2.2. Cell culture 
Mouse SCG cell culture was carried out as described previously 
(Martínez-Pinna et al., 2002; Romero et al., 2004; Lamas et al., 2009). Briefly, 
mice (20–60 d of age) were terminally anesthetized with CO2 and immediately 
decapitated. SCGs were removed and cleaned up in cold Leibowitz medium (L-
15) under a binocular microscope; then, the ganglia were chopped and 
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incubated in collagenase (2.5 mg/ml in HBSS) for 15 min at 37°C. After 
washing, the ganglia were then incubated for 30 min in trypsin (1 mg/ml in 
Hanks). Finally, neurons were mechanically isolated, centrifuged, and plated in 
35 mm Petri dishes previously coated with laminin (10 µg/ml in EBSS). Neurons 
were cultured for 1–2 d at 37°C and 5% CO2 in L-15 medium containing the 
following: 24 mM NaHCO3, 10% fetal calf serum, 2 mM L-glutamine, 38 mM D-
glucose, 100 UI/ml penicillin, 100 µg/ml streptomycin, and 50 ng/ml nerve 
growth factor.  
2.3. Perforated-patch whole-cell recording 
Electrophysiological recordings were performed at room temperature and 
under continuous perfusion (≈10 ml/min) using an Axopatch 200B amplifier 
(Molecular Devices). Two-step fire-polished patch pipettes, with a tip resistance 
of 2–4 MΩ, were used to record through perforated patches obtained with 
amphotericin B (75 µg/ml); patches with series resistance above 20 MΩ were 
discarded (Rae et al., 1991). Junction potential ≈5 mV was not corrected 
(Neher, 1992). Data were digitized through a Digidata 1440A and analysed and 
plotted using the pClamp10 software (Molecular Devices) and Origin 6.1 
(OriginLab Corp., Northampton, MA, USA). The sampling frequency was 10 kHz 
and recordings were low pass filtered at 5 kHz by the amplifier built-in filter. The 
recording pipette solution contained (in mM): 105 Cs-acetate, 25 CsCl, 3 MgCl2, 
0.5 CaCl2, and 20 HEPES, pH=7.2 with Tris 
(tris(hydroxymethyl)aminomethane). Standard bath solution contained (in mM): 
140 NaCl, 3 KCl, 1 MgCl2, 2 CaCl2, 10 D-glucose, and 10 HEPES, adjusted to 
pH 7.2 with Tris. Atropine (0.5 µM) and TTX (0.5 µM) were routinely added in 
order to block muscarinic receptors and voltage-dependent sodium channels, 
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respectively. Agonists and antagonists were applied using a fast-step perfusion 
system SF-77B (Warner Instruments, USA). 
2.4. Data analysis 
To determine the effect of lidocaine on IACh, we measured IACh peak 
evoked by 300 µM ACh alone or together with different lidocaine doses (0.1 µM 
– 10 mM). IAChs elicited in the presence of lidocaine were normalised to the IACh 
evoked by ACh alone (Control) and data were fitted, using the Origin 6.1 
software, to the following form of the Hill equation (1): 
I/Imax = [1 + (IC50/[ACh])nH]-1 
where I is the IACh peak elicited at 300 µM ACh (applied either alone or together 
with lidocaine), Imax is the maximum current recorded, IC50 is the lidocaine 
concentration required to inhibit one-half the maximum current, and nH is the Hill 
coefficient. 
The rate of desensitisation was determined by measuring the IACh 
amplitude elicited by 300 µM ACh, either alone or co-applied with 3 or 30 µM 
lidocaine, at different times after the current peak. The percentages of 
desensitisation were obtained using the equation (2): 
   Dti = [1 – (Iti /Ipeak)] x 100 
where Dti is the percentage of desensitisation at the specified time, Ipeak the 
peak current amplitude, and Iti the current amplitudes remaining 1, 2, and 3 s 
after the peak. 
2.5. Drugs 
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ACh, atropine sulphate, lidocaine, HEPES, L-15 Leibovitz medium, 
collagenase, HBSS, trypsin, laminin, EBSS, penicillin, streptomycin and 
reagents of general use were purchased from Sigma (St. Louis, MO, USA) 
2.6. Statistics 
The values given in the text and figures correspond to the mean±SEM. 
When comparing two-group means of normally distributed values, the Student’s 
t-test was used. Among-group differences were determined by the Kruskal–
Wallis analysis of variance on ranks; the comparison of groups was made using 
the Dunn’s test. A significance level of P<0.05 was considered for all cases.  
3. Results 
3.1. Lidocaine inhibits IACh in SCG neurons 
Cultured SCG neurons were patched and voltage-clamped at -60 mV, 
unless otherwise stated, by using the perforated-patch whole cell recording. For 
each experimental condition, recordings were made from neurons of 5-8 
independent cell cultures, unless otherwise stated. Fast application of ACh (300 
µM) for 5 s to a clamped neuron elicited a desensitising inward current (Lamas 
et al., 1997), which was due to the activation of nAChRs expressed by these 
neurons (Figure 1A, Control). When ACh (300 µM) was co-applied with different 
doses of lidocaine (0.1 µM to 10 mM), to the same neuron, the IACh peak 
decreased in a dose-dependent way (Figure 1A). Similar results were obtained 
in 7 different cells. The average dose-inhibition relationship (Figure 1B) was well 
fitted to a single sigmoid curve, from which could be estimated an IC50 of 41 µM 
and a slope (nH) of 0.90 ± 0.04. These results are in good agreement with those 
reported by Gentry and Lukas (2001) by measuring 86Rb+ efflux in SH-SY5Y 
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cells expressing α3β4 nAChRs (IC50 = 63; nH = 1.2), in spite of the 
methodological differences. 
3.2. Lidocaine effects on IACh desensitisation 
 Besides decreasing IACh peak, lidocaine modified the IACh inactivation 
kinetics of SCG neurons, and this effect was dependent on the lidocaine dose, 
as previously described for Torpedo nAChRs microtransplanted to Xenopus 
oocytes (Alberola-Die et al., 2011). Thus, co-application of a low dose of 
lidocaine (3 µM, which caused about 10% inhibition of IACh) with ACh (300 µM) 
did not affect IACh desensitisation (Dti values at 1, 2, and 3 s were: 34±5%, 
63±7%, and 76±6%, n=9, for ACh alone versus 41±8%, 65±8%, 77±7%, n=7, 
for ACh plus 3 µM lidocaine (p>0.05, ANOVA on ranks); see Figure 2A, B). 
However, higher doses of lidocaine (30 µM, close to the IC50), in the presence 
of ACh (300 µM), significantly accelerated IACh decay (Dti values at 1, 2, and 3 s 
were: 68±6%, 86±3%, 93±2%, n=7 (p<0.05, ANOVA on ranks); see Figure 2A, 
B). 
3.3. Lidocaine inhibition as a function of the membrane potential 
 To determine whether, or not, lidocaine blockade of IACh was voltage-
dependent, IAChs were elicited by applying ACh (100 µM) either alone (Figure 
3A1) or co-applied with lidocaine (100 µM; Figure 3A2), at different membrane 
potentials (from -80 to +20 mV, in steps of 20 mV). The current-voltage 
relationship (i/v) for the IAChs evoked by ACh alone (n=9), showed a reversal 
potential close to 0 mV and marked inward rectification (Figure 3A1, B, closed 
circles), similar to that described for nAChRs of rat sympathetic ganglion 
neurons (Lamas et al., 1997; Mathie et al., 1990). When lidocaine was co-
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applied with ACh (n=7) IACh reversal potential was not affected, but IACh 
amplitude decreased and the extent of inhibition depended on the membrane 
potential. Thus, a greater blockade was observed at more hyperpolarized 
potentials (Figure 3A2, B, open circles). This voltage-dependence of IACh 
inhibition by lidocaine is better shown by plotting the fraction of the IACh left by 
lidocaine versus membrane potential, which evidences, at negative potentials, a 
lineal function (Figure 3C). The voltage dependence could not be properly 
assessed at positive potentials, because of the marked inward rectification of 
IACh at these potentials (Figure 3B). Nevertheless, the value of fractional IACh left 
by lidocaine at 0 mV, estimated from the fitted line, was roughly 50%, indicating 
that still at this membrane potential there is an important blockade of nAChRs. 
This suggesting that lidocaine exerts also a voltage-independent blockade, as it 
has been previously reported for muscle-type nAChRs (Alberola-Die et al., 
2011) and for other related LAs, such as procaine (Adams, 1977). 
3.4. Lidocaine blockade of closed-state (resting) nAChRs  
 Given that lidocaine causes voltage-independent inhibition of IACh in SCG 
neurons, we wanted to know whether this particular blockade of nAChRs was 
due to the binding of lidocaine to closed-state receptors, as we previously 
reported for muscle-type nAChRs (Alberola-Die et al., 2011). We compared the 
degree of IACh inhibition obtained by pre-applying lidocaine (100 µM) for 12 s, 
and subsequently co-applying ACh (300 µM) plus lidocaine (100 µM) with that 
evoked by direct co-application of ACh and lidocaine, at the same doses. When 
lidocaine was pre-applied to a neuron before its co-application with ACh, the 
extent of IACh inhibition was much higher than that evoked, in the same neuron, 
by solely co-application of lidocaine and ACh (Figure 4A1 and A2). On average, 
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the percentage of IACh blockade reached 93±1% (n=5, from 3 independent cell 
cultures) and 65±3% (n=6; p<0.05, t-test), for responses evoked with and 
without lidocaine pre-application, respectively. This enhanced IACh inhibition 
elicited by lidocaine pre-application can be explained assuming that lidocaine 
blocks closed-state nAChRs, and so, precludes their opening when lidocaine is 
subsequently co-applied with ACh (Alberola-Die et al., 2011). 
4. Discussion 
These results show that lidocaine mechanisms of action on neuronal 
heteromeric nAChR present in the peripheral nervous system are similar to 
those previously reported by Alberola-Die et al. (2011) for muscle-type nAChRs. 
The similarity of the actions evoked by lidocaine in dissociated SCG neurons 
and in oocytes microtransplanted with muscle-type nAChR has two relevant 
implications: i) It indicates that lidocaine has similar modulating actions on 
different heteromeric nAChRs, including muscle-type and α3β4 nAChRs, which 
is the main subtype in sympathetic neurons; but also most likely over α3β4α5 
and α3β4β2, which together constitute almost half the number of nAChRs in the 
mouse SCG neurons (David et al., 2010). This being of particular interest 
because many molecules acting on nAChRs have marked specificity on 
particular subtypes. So, for instance, whereas BW284c51, a quaternary-
ammonium cholinesterase inhibitor, is a powerful inhibitor of muscle-type 
nAChRs (Olivera-Bravo et al., 2005, 2007) it barely blocks either heteromeric 
α4β2 or homomeric α7 nAChRs (Fayuk and Yakel, 2004). Similarly, niflumic 
and flufenamic acids inhibit α3β2 but potentiate α3β4 nAChRs (Zwart et al., 
1995). ii) The effects evoked by lidocaine on nAChRs in either SCG neurons or 
muscle fibres have some similarities to those described for other members of 
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the Cys-loop family of receptors. So, lidocaine inhibits, though at higher 
concentrations, glycine and GABAA receptors expressed in oocytes (Hara and 
Sata, 2007), although its mechanisms of blockade remain to be elucidated. 
Furthermore, it has been recently shown that lidocaine, and other quaternary 
ammonium compounds, also blocks prokaryotic pentameric ligand-gated 
channels (GLIC, protein from Gloeobacter violaceous), by its binding within the 
channel pore, causing a voltage-dependent blockade (Hilf et al., 2010), which is 
something similar to that we found for neuronal nAChRs from SCG neurons. 
Nevertheless, from our results, lidocaine must also bind to other regions of 
heteromeric nAChRs, since it also caused closed-channel blockade and 
changes in desensitisation, which cannot be explained by a single binding site 
in heteromeric nAChRs.  
 It should be emphasized that lidocaine is a compound widely used in 
clinical practice as LA and also as antiarrhythmic drug (class I) (Sheets et al., 
2010). For nerve blockade therapies, or for epidural or spinal anaesthesia, 
lidocaine is commonly administered at doses of 0.5-5% (20-200 mM) (Covino 
and Wildsmith, 1998), reaching the target area at concentrations in the 
millimolar range, to warrant an effective blockade of voltage-dependent Na+ 
channels. Thus, at these concentrations, lidocaine will have relevant direct 
blocking actions on nAChRs of muscle fibers and vegetative ganglia, given that 
their IC50 is far below 1 mM.  
In conclusion, these results confirm and extend previous studies on the 
mechanisms of modulation of neuronal nAChRs by lidocaine, providing new 
evidences supporting that neuronal heteromeric nAChRs expressed in 
sympathetic neurons are strongly modulated by lidocaine, which inhibits these 
13 
 
receptors by different and independent ways. It remains to be known whether 
heteromeric nAChR in the central nervous system, mainly of the α4β2 subtype, 
and the homomeric α7 nAChRs, are similarly modulated by lidocaine or other 
LAs. 
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FIGURE LEGENDS: 
Figure 1. Lidocaine inhibits IAChs in SCG neurons. (A) Superimposed 
recordings of IAChs obtained in the same SCG neuron by applying, for 5 s, ACh 
either alone (300 µM, Control) or with the indicated doses of lidocaine (+ 3, 10, 
30, 100, 300 or 1000 µM Lid). In this and following figures, the bar above the 
records indicates the application span, and the holding potential was -60 mV, 
unless otherwise stated. IAChs were obtained at intervals of 5 min, in order to 
minimize desensitisation effects. (B) Dose-IACh inhibition relationship for 
lidocaine. IAChs evoked in the presence of lidocaine were normalised to the IACh 
elicited by ACh alone. Each point corresponds to the mean±S.E.M. of 5-7 
different cells and solid line represents the fitting to a sigmoid curve (see 
equation 1, Materials and methods). 
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Figure 2. Lidocaine effects on IACh desensitisation. (A) Superimposed IACh 
records elicited by ACh (300 µM) applied either alone (Control, black) or plus 
lidocaine at two different doses (3 or 30 µM, red). Records are normalised to the 
same size in order to better compare the inactivation kinetics. (B) Graph 
showing the percentage of IACh desensitisation at different times (1, 2, and 3 s) 
after IACh peak, when neurons were superfused with ACh (300 µM) alone 
(closed circles and black line, n=9), or co-applied with either 3 µM lidocaine 
(open red circles and red line, n=7) or 30 µM lidocaine (open red triangles and 
red line, n=7). Data are the mean±S.E.M. and asterisks indicate significant 
differences with the control values (p<0.05, ANOVA on ranks). 
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Figure 3. Lidocaine blocks nAChRs in a voltage-dependent manner. (A1 and 
A2) Superimposed recordings of IAChs evoked, in the same neuron, by 100 µM 
ACh either alone (A1) or co-applied with 100 µM lidocaine (A2), while clampling 
the cell at different holding potentials (values on the right, in mV). (B) i/v 
relationships of the IAchs elicited at each voltage, (normalised to the IACh evoked 
by ACh alone at -60 mV; each point is the average±S.E.M. of 5-9 neurons), in 
presence of ACh alone (100 µM, filled circles) or co-applied with lidocaine (100 
µM, open circles). For some points, the error bar is within the symbol. (C) Plot of 
the fraction of the IAch left by lidocaine (IACh+Lid), normalised to the control IACh, 
against the membrane potential, showing the voltage-dependent blockade of 
nAChRs by lidocaine. Each data is the mean±S.E.M. of, at least, 5 cells. 
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Figure 4. Inhibition of nAChRs by lidocaine pre-application. (A1) Representative 
IAChs records elicited, in the same neuron, by 300 µM ACh either alone (Control, 
black record), or plus 100 µM lidocaine after pre-applying lidocaine, at the same 
concentration, for 12 s (+ 100 µM Lid, red recording). (A2) IAChs evoked by 300 
µM ACh alone (Control, black record) or co-applied with 100 µM lidocaine (+ 
100 µM Lid, red recording), without lidocaine pre-application. (B) Column graph 
showing the percentage of IACh inhibition when 300 µM ACh and 100 µM 
lidocaine were co-applied with (n=5) or without (n=6) a 12 s lidocaine pre-
application. Data are the mean±S.E.M. and the asterisk indicates significant 
differences between groups (p<0.05, t-test). 
